OnDemand Wills Eye Ophthalmology Review Course

Saturday, March 6, 2021, 12:00 AM - Friday, February 11, 2022, 12:00 AM


AMA PRA Category 1 Credits™ (63.50 hours), Non-Physician Attendance (63.50 hours)

The premier Ophthalmic review course nationally and internationally, the Wills Eye Hospital Review Course features world-renowned experts providing a comprehensive and intensive review of the basic principles in each subspecialty of ophthalmology along with recent advances. Course participants will be well prepared to sit for the OKAPS, ABO or MOC exams. The course is also an excellent refresher for practicing ophthalmologists. the course will be delivered virtually as a self-guided on-demand learning activity.

1. Provide a comprehensive review of topics in ophthalmology including: Optics and Refraction; Anatomy and Embryology; Retina and Vitreous; Ocular Pathology; Orbit, Eyelid and Lacrimal System; Pharmacology and Therapeutics; Ocular Tumors; Neuro-Ophthalmology; Corneal and External Diseases; Uveitis and AIDS; Glaucoma; Pediatric Ophthalmology and Strabismus; CT and MRI Imaging of Eye and Orbit.
2. Better understand the pathophysiology of most ophthalmic disease.
3. Perform appropriate dignostic tests and differential diagnosis for most ophthalmic diseases.
4. Apply the knowledge to optimally treat patients with ophthalmic diseases.

Wills Eye Hospital designates this Enduring Material educational activity for a maximum of 63.50 AMA PRA Category 1 Credits^TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based on scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about all financial relationships they have with commercial entities whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships have been mitigated.